Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years
Open Access
- 16 September 2012
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (9) , 1259-1271
Abstract
This was a multicenter, blinded, Phase II study (NCT00880893) conducted in Singapore. The primary objectives were to evaluate the safety of a tetravalent dengue vaccine (TDV) comprising four recomb...Keywords
This publication has 30 references indexed in Scilit:
- Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in HumansThe American Journal of Tropical Medicine and Hygiene, 2011
- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineVaccine, 2011
- Dengue Virus Surveillance for Early Warning, SingaporeEmerging Infectious Diseases, 2010
- Early diagnosis of dengue in travelers: Comparison of a novel real-time RT-PCR, NS1 antigen detection and serologyJournal of Clinical Virology, 2010
- Overview of theFlaviviridaeWith an Emphasis on the Japanese Encephalitis Group VirusesLaboratory Medicine, 2009
- DengueThe Lancet, 2007
- Dengue hemorrhagic fever with special emphasis on immunopathogenesisComparative Immunology, Microbiology and Infectious Diseases, 2007
- Modelling the control strategies against dengue in SingaporeEpidemiology and Infection, 2007
- Dengue in the Americas and Southeast Asia: do they differ?Revista Panamericana de Salud Pública, 2006
- Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue virusesNature Medicine, 2004